Celcuity (CELC) is trading higher today as investors revisit the company’s near-term regulatory catalyst for gedatolisib, its lead breast cancer drug candidate. The FDA has granted Priority Review for the New Drug Application, with a PDUFA goal date set for July 17, 2026, keeping attention on a defined approval timeline that can drive positioning and momentum into the decision window. (ir.celcuity.com)

Gedatolisib is being reviewed for HR+/HER2-/PIK3CA wild-type advanced breast cancer, an indication where investors see potential for a first commercial product and a step-change in Celcuity’s profile from clinical-stage biotech to commercial-stage oncology company. The company has highlighted a broader corporate push toward launch readiness, which tends to amplify market sensitivity to FDA timeline milestones as the decision date approaches. (ir.celcuity.com)

The rally is also supported by improved confidence around funding as Celcuity has pointed to $30 million of debt financing alongside its commercialization buildout. Investors often treat incremental non-dilutive funding as a positive signal in late-stage biotech, particularly when expenses rise ahead of a potential launch, though it can also increase leverage and execution pressure. (simplywall.st)

Beyond the FDA decision, traders are watching for additional clinical and operational milestones that could re-rate expectations into mid-2026. Celcuity has said topline results from the PIK3CA mutant cohort of its Phase 3 VIKTORIA-1 study are expected in the second quarter of 2026, creating another potential catalyst ahead of the July 17, 2026 PDUFA date. (ir.celcuity.com)